A novel peptide from Bombina maxima frog skin binds bacterial LPS with nanomolar affinity (KD 1.05 × 10⁻⁹ M) and protected mice from lethal endotoxin shock by neutralizing the toxin and reducing inflammatory cytokines.
KD = 1.05 × 10⁻⁹ MThe frog peptide binds bacterial LPS with nanomolar affinity — strong enough to neutralize the toxin and protect mice from lethal endotoxin shock
What the researchers found
Peptide 2 (LVGKLLKGAVGDVCGLLPIC) binds LPS with KD of 1.05 × 10⁻⁹ M, inhibits TNF-α and IL-6, has low hemolytic activity and cytotoxicity, and protected mice from LPS-induced death.
Why it matters
Sepsis kills more than 11 million people annually worldwide. A peptide that directly neutralizes the bacterial toxin driving sepsis could save lives where antibiotics alone fail — addressing a critical unmet medical need.
The numbers in context
KD 1.05 x 10^-9 M; 20 amino acids; reduced TNF-alpha and IL-6; protected mice from LPS death; low hemolysis
How the study worked
Peptide identified from B. maxima skin secretions after LPS challenge. Characterized for hemolytic activity, cytotoxicity (RAW 264.7 cells), anti-inflammatory activity (TNF-α, IL-6 inhibition), LPS binding (biolayer interferometry), and in vivo survival study in LPS-challenged mice.
Who was studied
RAW 264.7 cells (in vitro) and mice (in vivo LPS challenge)
What this study cannot tell us
Single peptide tested. Mouse LPS challenge model may differ from human sepsis. Peptide stability, pharmacokinetics, and manufacturing scalability not assessed. In vivo anti-sepsis efficacy in infection models (not just LPS challenge) not tested.
How to read the evidence
Moderate evidence: comprehensive in vitro characterization plus in vivo survival data in mice. No human data, but mouse survival is a strong preclinical endpoint.
When this study was published
Published 2021. Anti-LPS peptide development for sepsis continues with growing interest in peptide-based neutralization approaches.
The bigger picture
Frog skin peptides are one of nature's richest sources of bioactive molecules. This discovery adds to the growing toolkit of antimicrobial peptides that could address the antibiotic resistance crisis and the specific challenge of neutralizing bacterial toxins in sepsis.
Questions still open
- Would this peptide be effective in actual bacterial infection models, not just purified LPS challenge?
- Can the peptide be stabilized for clinical development?
- Could it be combined with antibiotics for synergistic anti-sepsis therapy?
Common questions
How does this peptide fight sepsis?
Why study frog skin for sepsis drugs?
Read the original research
A novel peptide identified from skin secretions of Bombina maxima possesses LPS-neutralizing activity.
Biochemical and biophysical research communications, 550, 107-112
Citation
Guo, Caifen; Li, Jian; Lee, WenHui; Li, Hao; Shen, Jihong; Zhang, Baiyu. (2021). A novel peptide identified from skin secretions of Bombina maxima possesses LPS-neutralizing activity.. Biochemical and biophysical research communications, 550, 107-112. https://doi.org/10.1016/j.bbrc.2021.02.131